Procept Biorobotics Corp (PRCT) Stock Price, Quote & News

Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 232 7200

Website: www.procept-biorobotics.com

Address:

150 Baytech Drive, San Jose, United States

Cinematix Jul. 31 at 8:56 PM

$PRCT Anything under $50 is a good buy for me.

0 · Reply

Muddymac Jul. 26 at 4:46 PM

$PRCT From last year to this year, capital sales have dropped from almost half of revenue to 27%. This is going to become a utilization growth game very soon. Very different strategy and execution to grow procedural growth at the same accounts than opening new accounts with an expensive capital purchase. Let’s see how they do with a new CEO starting in Sept.

1 · Reply

SOFIdude Jul. 25 at 10:51 AM

$PRCT https://ir.procept-biorobotics.com/news-releases/news-release-details/ambulatory-surgery-center-completes-water-iv-trial-procedures

0 · Reply

SOFIdude Jul. 25 at 10:43 AM

$PRCT https://www.tipranks.com/news/the-fly/procept-biorobotics-sees-q2-revenue-79-2m-consensus-75-94m-thefly#google_vignette

0 · Reply

Markpokoron Jul. 19 at 4:30 AM

$PRCT broke a major trendline. Eyes on how it reacts here.

0 · Reply

JasonCO Jul. 18 at 7:53 PM

$PRCT besutiful pump and dump today mm no one fooled

1 · Reply

StockHunter75 Jul. 15 at 2:28 PM

$PRCT Buying some

0 · Reply

JarvisFlow Jul. 15 at 1:12 PM

Morgan Stanley updates rating for PROCEPT BioRobotics ( $PRCT ) to Overweight, target set at 71 → 68.

0 · Reply

Quantumup Jul. 15 at 1:07 PM

BofA reit'd $PRCT Buy-$84 after Center of Medicare and Medicaid Services (CMS) released its proposed physician fee schedule (PFS) for 2026 which includes what a doctor will get paid to perform PRCT's Aquablation under its new Category I CPT code. $BSX $ISRG $SYK $MDT GEHC BofA said in its note:

0 · Reply

Lambster2 Jul. 15 at 11:39 AM

$PRCT Procept BioRobotics Corp (NASDAQ: PRCT) Buy (1) ESG Score: 67/100 Price Target: $85.00 CMS Proposed PFS Aquablation Reimbursement Lower vs Prior Assumption THE TD COWEN INSIGHT CMCMS proposed a 2026 Medicare physician payment of ~$542 for Aquablation under a new Category I CPT code - below our ~$600 estimate that we published last night. The impact of lower physician reimbursement level on Aquablation adoption and utilization will continue to be debated and the overhang may not be fully removed in the near term.

0 · Reply

PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO

Jul 23, 2025, 8:00 AM EDT - 10 days ago

Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy

Jul 21, 2025, 4:03 PM EDT - 12 days ago

PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 14, 2025, 9:15 PM EDT - 18 days ago

Aquablation® Therapy's Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule

May 17, 2025, 7:00 AM EDT - 2 months ago

19 stocks at the intersection of AI and robotics that could see big sales boosts

AI AMBA CLS HSAI IOT ISRG NOW

Apr 29, 2025, 4:03 PM EDT - 3 months ago

PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June

Apr 24, 2025, 4:03 PM EDT - 3 months ago

PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops

Apr 24, 2025, 2:37 PM EDT - 3 months ago

PROCEPT BioRobotics Corporation (PRCT) Q1 2025 Earnings Call Transcript

Apr 24, 2025, 7:00 AM EDT - 3 months ago

PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Apr 10, 2025, 4:03 PM EDT - 4 months ago

PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas

Mar 24, 2025, 8:00 AM EDT - 4 months ago

WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation

Mar 14, 2025, 8:00 AM EDT - 5 months ago

PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada

Mar 11, 2025, 4:42 AM EDT - 5 months ago

Procept BioRobotics: Strong Growth, But Profitability Seems Far Away

Feb 25, 2025, 4:02 PM EST - 5 months ago

PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results

Feb 7, 2025, 8:00 AM EST - 6 months ago

PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference

Jan 16, 2025, 9:00 AM EST - 7 months ago

Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on PROCEPT BioRobotics (NASDAQ: PRCT)

Nov 26, 2024, 4:05 PM EST - 8 months ago

PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024

Nov 26, 2024, 5:10 AM EST - 8 months ago

Procept BioRobotics: Continued Growth Runway Ahead

Oct 29, 2024, 8:43 PM EDT - 9 months ago

PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock

Oct 28, 2024, 4:19 PM EDT - 9 months ago

PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock

Oct 28, 2024, 2:17 PM EDT - 9 months ago

Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential

Oct 28, 2024, 10:32 AM EDT - 9 months ago

PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 7:00 AM EDT - 9 months ago

PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance

Oct 9, 2024, 4:04 PM EDT - 10 months ago

PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024

Oct 7, 2024, 4:04 PM EDT - 10 months ago

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer

Aug 28, 2024, 4:03 PM EDT - 1 year ago

PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Aug 21, 2024, 7:00 AM EDT - 1 year ago

PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy

Aug 3, 2024, 9:23 PM EDT - 1 year ago

PROCEPT BioRobotics Corporation (PRCT) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:03 PM EDT - 1 year ago

PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance

Jul 15, 2024, 4:03 PM EDT - 1 year ago

PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024

Jun 17, 2024, 4:03 PM EDT - 1 year ago

PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy

Jun 3, 2024, 4:03 PM EDT - 1 year ago

PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024

May 13, 2024, 4:05 PM EDT - 1 year ago

PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference

May 6, 2024, 8:00 AM EDT - 1 year ago

Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia

May 1, 2024, 12:56 PM EDT - 1 year ago

PROCEPT BioRobotics Corporation (PRCT) Q1 2024 Earnings Call Transcript

May 1, 2024, 7:00 AM EDT - 1 year ago

PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Apr 23, 2024, 8:00 AM EDT - 1 year ago

PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting

Apr 4, 2024, 4:04 PM EDT - 1 year ago

PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas

Apr 2, 2024, 4:03 PM EDT - 1 year ago

PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024

Feb 28, 2024, 12:09 AM EST - 1 year ago

PROCEPT BioRobotics Corporation (PRCT) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 4:02 PM EST - 1 year ago

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results

Feb 12, 2024, 4:05 PM EST - 1 year ago

PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston

Jan 8, 2024, 5:00 PM EST - 1 year ago

PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million

Nov 13, 2023, 4:03 PM EST - 1 year ago

PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City

Nov 2, 2023, 12:01 AM EDT - 1 year ago

PROCEPT BioRobotics Corporation (PRCT) Q3 2023 Earnings Call Transcript

Nov 1, 2023, 4:02 PM EDT - 1 year ago

PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

Oct 16, 2023, 4:05 PM EDT - 1 year ago

PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023

Aug 22, 2023, 8:00 AM EDT - 2 years ago

PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan

Aug 17, 2023, 4:05 PM EDT - 2 years ago

PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston

Cinematix Jul. 31 at 8:56 PM

$PRCT Anything under $50 is a good buy for me.

0 · Reply

Muddymac Jul. 26 at 4:46 PM

1 · Reply

SOFIdude Jul. 25 at 10:51 AM

$PRCT https://ir.procept-biorobotics.com/news-releases/news-release-details/ambulatory-surgery-center-completes-water-iv-trial-procedures

0 · Reply

SOFIdude Jul. 25 at 10:43 AM

$PRCT https://www.tipranks.com/news/the-fly/procept-biorobotics-sees-q2-revenue-79-2m-consensus-75-94m-thefly#google_vignette

0 · Reply

Markpokoron Jul. 19 at 4:30 AM

$PRCT broke a major trendline. Eyes on how it reacts here.

0 · Reply

JasonCO Jul. 18 at 7:53 PM

$PRCT besutiful pump and dump today mm no one fooled

1 · Reply

StockHunter75 Jul. 15 at 2:28 PM

$PRCT Buying some

0 · Reply

JarvisFlow Jul. 15 at 1:12 PM

Morgan Stanley updates rating for PROCEPT BioRobotics ( $PRCT ) to Overweight, target set at 71 → 68.

0 · Reply

Quantumup Jul. 15 at 1:07 PM

0 · Reply

Lambster2 Jul. 15 at 11:39 AM

0 · Reply

DonCorleone77 Jul. 15 at 3:30 AM

$DASH $JD $NFLX $PRCT $SOUN Hello Everyone, I have now posted information regarding analyst reports/notes for the companies mentioned in the re-shared post below. I hope this information is useful to everyone. Best, DC77

0 · Reply

DonCorleone77 Jul. 15 at 3:26 AM

$PRCT Information regarding Wells Fargo analyst report on PRCT issued yesterday: https://x.com/CorleoneDon77/status/1944959991955234865

0 · Reply

DonCorleone77 Jul. 14 at 7:21 PM

$DASH $JD $NFLX $PRCT $SOUN Hey Everyone, In addition to the information relating to company analyst reports/notes that I posted today, I will also be posting information regarding analyst reports/notes this evening for the following companies: 1) AZN 2) CLF 3) COIN 4) CORZ 5) CRWD 6) DASH 7) JD 8) NFLX 9) PRCT 10) SOUN Feel free to check back this evening if any of these companies are of interest to you. I hope this information is useful to many members. Best, DC77

1 · Reply

GoldenTradesCapital Jul. 11 at 12:31 PM

STOCK RECOMMENDATION: $PRCT – ROBOTIC SURGERY INNOVATOR 🔬 Procept Biorobotics is disrupting urology with precision tech. Small cap, high growth. Follow us for next-gen medtech stocks 🔱

0 · Reply

Src947 Jul. 11 at 9:32 AM

$PRCT July calls acting funny….$65 calls bid $1.

0 · Reply

HodlMaBeer Jul. 9 at 5:12 PM

$PRCT wake up!!

0 · Reply

Quantumup Jul. 9 at 1:08 PM

Stephens🏁 $PRCT Overweight-$70 and said "Premium Price, Premium Potential: A Surgical Disruptor in BPH; Initiating OW-Vol./$70 PT" $BSX $ISRG $SYK $MDT #BPH #PCa Stephens said in its note that it expects $PRCT to post robust growth and margin expansion as adoption of Aquablation continues to expand. Stephens added: ● Aquablation is disrupting the benign prostatic hyperplasia (BPH) market by taking share from existing procedures and capturing patients who historically delayed or avoided surgery. ● Believes expanding into prostate cancer has the potential to drive meaningful growth longer-term.

0 · Reply

JarvisFlow Jul. 7 at 1:52 PM

Oppenheimer has updated their rating for PROCEPT BioRobotics ( $PRCT ) to Perform.

0 · Reply

DoctorTy Jul. 6 at 8:54 PM

$PRCT this will be 200$ stock in 2-3 years .AI and robotic surgery will be huge. May be bigger than anything

0 · Reply

Spd2base Jun. 25 at 9:52 PM

$PRCT why does overnight price not show on Robinhood?

0 · Reply

Quantumup Jun. 18 at 2:23 PM

Truist reiterated $PRCT Buy-$70. $BSX $ISRG $MDT $TNDM SYK Truist said in its note: "We believe gdce continues to leave room for upside given mgmt. commentary (a) it's trying to be conservative (still early in yr) (b) healthy March utilization momentum is carrying over into April/May, and (c) CFO Waters continues to emphasize a high degree of confidence on capital pipeline leads as well as increasingly predictable capital conversions (helped by more IDN placements). Mgmt. sees handpiece gdce continuing to set-up for beat & raises, and the decision to exercise "restraint"---holding back a bigger initial raise following the 1Q handpiece upside---was made in this vein (to guide conservatively early in the year)."

0 · Reply

QES Jun. 12 at 12:42 AM

$PROF How PROF compares to $PRCT PROF is the clear winner

3 · Reply

Market Cap	2.68B
Revenue (ttm)	224.50M
Net Income (ttm)	-91.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-40.72%
Debt to Equity Ratio	0.14

Volume	1,284,600
Avg Vol	945,996
Day's Range	N/A - N/A
Shares Out	55.33M
Stochastic %K	21%
Beta	1.07
Analysts	Strong Sell
Price Target	$75.78